Бизнес · 15.04.20111 мин чтения
Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN; Correction
Локальный автоматический перевод · Язык оригинального источника
Краткое содержание
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of March 21, 2011 (76 FR 15323). The document announced the determination of the regulatory review period for ATRYN. The document was published with an incorrect docket number. This document corrects that error.